EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
EPRS was delisted on the 3rd of August, 2016.
37 hedge funds and large institutions have $35.1M invested in EPIRUS BIOPHARMACEUTICALS INC COM in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 9 closing their positions.
18% less funds holding
Funds holding: 45 → 37 (-8)
36% less capital inflows, than outflows
Capital inflows: $1.81M | Capital outflows: $2.82M
40% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 15
89% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bailard
Foster City,
California
|
+$1.6M |
| 2 |
SM
Southport Management
Wilson,
Wyoming
|
+$70.2K |
| 3 |
Jennison Associates
New York
|
+$42.9K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.9K |
| 5 |
Bank of New York Mellon
New York
|
+$39.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Broadfin Capital
New York
|
-$829K |
| 2 |
Highland Capital Management (Texas)
Dallas,
Texas
|
-$697K |
| 3 |
Spark Investment Management
New York
|
-$290K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$281K |
| 5 |
Spot Trading
Chicago,
Illinois
|
-$187K |
EPRS Hedge Fund Activity: Q1 2016 in Review
37 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) for Q1 2016, worth a combined $35.1M — down 15% from $41.3M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of EPRS and 1 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 9 added.
The largest buyer was Bailard, adding an estimated $1.6M. The largest seller was Broadfin Capital, cutting an estimated $829K.
- 37 institutional investors held EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) as of Q1 2016, down from 45 in Q4 2015.
- Funds reported $35.1M of EPIRUS BIOPHARMACEUTICALS INC COM stock for Q1 2016, down 15% quarter-over-quarter.
- 1 fund opened new EPIRUS BIOPHARMACEUTICALS INC COM positions in Q1 2016 and 9 closed out, a net change of -8 holders.
- The largest EPIRUS BIOPHARMACEUTICALS INC COM buyer in Q1 2016 was Bailard, an estimated $1.6M added.
- The largest EPIRUS BIOPHARMACEUTICALS INC COM seller in Q1 2016 was Broadfin Capital, an estimated $829K sold.
Based on aggregated 13F filings for Q1 2016.